Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 9/20 | 0.87 |
| ▸ | LMNA | P02545 | 8/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.87 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.87 |
| ▸ | PGR | P06401 | 4/20 | 0.87 |
| ▸ | CNR1 | P21554 | 2/20 | 0.87 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.87 |
| ▸ | MAPT | P10636 | 2/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.87 |
| ▸ | USP2 | O75604 | 1/20 | 0.87 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | AR | P10275 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14884636 | 1.00 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL28971361 | 1.00 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL11422147 | 1.00 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL15975096 | 1.00 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL1973547 | 0.94 | HIF1A (0.81) | HIF1ALMNACYP3A4NR3C1PGR | |
| Amcinonide SCHEMBL13026154 | 0.93 | HIF1A (1.00) | HIF1ALMNACYP3A4NR3C1PGR | |
| Amcinonide SCHEMBL5488922 | 0.93 | HIF1A (1.00) | HIF1ALMNACYP3A4NR3C1PGR | |
| Amcinonide SCHEMBL4720 | 0.93 | HIF1A (1.00) | HIF1ALMNACYP3A4NR3C1PGR | |
| Amcinonide SCHEMBL21051752 | 0.93 | HIF1A (1.00) | HIF1ALMNACYP3A4NR3C1PGR | |
| Amcinonide SCHEMBL1649481 | 0.93 | HIF1A (1.00) | HIF1ALMNACYP3A4NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1520 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504786-A1 | ENGINEERED CD200R ANTIBODIES AND USES THEREOF | MiroBio Limited (GB) | 2025-02-12 | — | — | EP | claimed |
| CN-118141762-B | Foam-type pharmaceutical agent and foam composition for topical application | 北京罗诺强施医药技术研发中心有限公司 | 2024-07-12 | — | — | CN | claimed |
| WO-2024067327-A1 | USE OF TRITERPENOID SAPONIN COMPOUND IN PREPARATION OF MEDICAMENT FOR PREVENTING AND/OR TREATING NODULE, FIBROSIS, OR GRANULOMA DISEASES | 浙江普利药业有限公司 | 2024-04-04 | — | — | WO | claimed |
| US-20230416361-A1 | ENGINEERED CD200R ANTIBODIES AND USES THEREOF | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-12-28 | — | — | US | claimed |
| WO-2023196866-A1 | ENGINEERED CD200R ANTIBODIES AND USES THEREOF | MIROBIO LIMITED (GB) | 2023-10-12 | — | — | WO | claimed |
| CN-116406296-A | Treatment of lupus attacks | 阿斯利康(瑞典)有限公司 | 2023-07-07 | — | — | CN | claimed |
| US-20210315842-A1 | STABLE PHARMACEUTICAL COMPOSITIONS FOR PRESSURIZED METERED DOSE INHALERS | LUPIN INC (US) | 2021-10-14 | — | — | US | claimed |
| CN-112702993-A | Pharmaceutical compositions suitable for joint delivery and their use in the treatment of joint pain | TLC生物医药公司 | 2021-04-23 | — | — | CN | claimed |
| EP-3801457-A1 | STABLE PHARMACEUTICAL COMPOSITIONS FOR PRESSURIZED METERED DOSE INHALERS | Lupin Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| US-20210000758-A1 | TREATMENT OF OCULAR DISEASES WITH OPHTHALMIC TAPINAROF COMPOSITIONS | SOL-GEL TECHNOLOGIES LTD. (IL) | 2021-01-07 | — | — | US | claimed |
| EP-1180020-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | Acusphere, Inc. (US) | 2002-02-20 | — | — | EP | claimed |
| US-20020013320-A1 | Use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease | BUSCH FRANK ROBERT (US) | 2002-01-31 | — | — | US | claimed |
| WO-2000072827-A9 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE INC (US) | 2002-01-31 | — | — | WO | claimed |
| EP-1166778-A2 | The use of growth hormone scretagogues to treat systemic lupus erythematosus and inflammatory bowel disease | Pfizer Products Inc. (US) | 2002-01-02 | — | — | EP | claimed |
| US-6203813-B1 | OPIATE ANTAGONIST, STEROIDAL ANTIINFLAMMATORY AGENT AND CARRIER; SUSTAINED RELEASE; DRUG ABUSE TREATMENT | GOOBERMAN, LANCE L. | 2001-03-20 | — | — | US | claimed |
| WO-2000072827-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE, INC. (US) | 2000-12-07 | — | — | WO | claimed |
| WO-2000057845-A1 | METHOD FOR REMOVAL OF HUMAN HORNY TISSUES | JOHNSON AND JOHNSON CONSUMER COMPANIES, INC. (US) | 2000-10-05 | — | — | WO | claimed |
| CN-1239656-A | Compound transdermal nicotine-clonidine paster for giving up smoking | UNIV CHONGQING MEDICAL (CN) | 1999-12-29 | — | — | CN | claimed |
| US-4944939-A | Mixture of salicylic acid, glucocorticoid, and sulfur | MOORE MILTON D (US) | 1990-07-31 | — | — | US | claimed |
| US-4478818-A | Ocular preparation housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1984-10-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013320-A1 | Use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease | GHSR, GHRHR, CRH | HIF1A 1681/4885LMNA 2598/4885CYP3A4 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.